The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 19.25
Bid: 19.00
Ask: 19.50
Change: -0.25 (-1.28%)
Spread: 0.50 (2.632%)
Open: 19.50
High: 19.50
Low: 18.50
Prev. Close: 19.50
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Geomerics Announces Agreement with Epic Games

25 Jul 2011 07:00

RNS Number : 9301K
Angle PLC
25 July 2011
 



For immediate release

25 July 2011

 

ANGLE plc

("ANGLE" or the "Company")

 

PORTFOLIO COMPANY GEOMERICS ANNOUNCES AGREEMENT WITH EPIC GAMES

 

ANGLE plc, which focuses on the commercialisation of technology, is pleased to announce that its 33% owned portfolio company Geomerics, has joined Epic Games' prestigious Unreal Engine 3 Integrated Partners Programme.

The powerful integration of Geomerics premier cross-platform lighting solution, Enlighten, with Epic's award winning Unreal Engine 3 provides a com--pelling proposition for computer games developers. Through its membership in Epic's Unreal Engine 3 Integrated Partners Programme, Geomerics maintains code and feature parity for Enlighten in step with the engine as it evolves.

Epic's Unreal Engine 3 is designed to accelerate developers' productivity for computer and video games, mobile games and applications, training stimulations, 3D visualisations, digital films and animated televisions shows. Unreal Engine 3 is the current holder and five-time winner of Game Developer magasine's Best Engine award in the US. It is available across multiple platforms including iOS, Xbox360® and Playstation®3, PC, Mac and Android.

Geomerics' Enlighten empowers game developers by providing the ability to update all aspects of indirect lighting in real time, in game, on PC and console. Enlighten is optimised to run on Playstation®3, Xbox 360™ and PC. It is available as a stand-alone SDK, or pre-integrated into UE3.

 

Andrew Newland, Chief Executive of ANGLE commented: 

"This agreement with Epic, one of the world's leading and most successful games developers, is a great endorsement of Geomerics' cutting edge dynamic lighting technology. Association with Epic with its established customer base and trusted industry relationships can only be beneficial for Geomerics as it continues to grow its sales base."

 

 

For further information:

ANGLE plc

01483 685830

Andrew Newland, Chief Executive

Ian Griffiths, Finance Director

 

Collins Stewart Europe Limited

Matt Goode

 

0207 523 8325

Buchanan

Lisa Baderoon, Catherine Breen

 

0207 466 5000

Scott Harris

Stephen Scott, James O'Shaughnessy, Harry Dee

 

0207 653 0030

 

 

About Epic Games

Epic Games, Inc., based in Cary, NC and established in 1991, develops cutting-edge games and cross-platform game engine technology. The company has created multiple million-selling, award-winning titles in its "Unreal" series, including "Unreal Tournament 3" for PC, PlayStation®3 and Xbox 360®. Epic's "Gears of War" franchise has sold more than 13 million copies worldwide and won more than 50 Game of the Year awards. Epic's Unreal Engine 3 is the five-time winner of and Hall of Fame inductee for Game Developer magazine's Best Engine Front Line Award. Unreal Engine 3 has also held the Develop Industry Excellence Award in its category for the past three years. Additional information about Epic can be obtained at www.epicgames.com.

 

About Geomerics

Geomerics, a 33% owned ANGLE portfolio company, is an innovation-led company developing cutting-edge graphics technology for the games industry. The company is based in Cambridge, UK, and has built a team that combines world class management and games industry experience with some of the UK's leading researchers. They are partners with many of the leading companies in the games industry and are currently working with developers around the world on AAA titles for release in 2011 and beyond.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRLLFESDVIFFIL
Date   Source Headline
21st Oct 20226:15 pmRNSIssue of Equity
18th Oct 20227:00 amRNSStreamlining of operations to increase cash runway
17th Oct 20222:23 pmRNSTR-1: Notification of major holdings
12th Oct 20227:00 amRNSFirst regional distribution agreement
30th Sep 20225:30 pmRNSIssue of Equity
30th Sep 20225:30 pmRNSHolding(s) in Company
29th Sep 20227:00 amRNSInterim Results
29th Sep 20227:00 amRNSPositive headline results from ovarian study
28th Sep 20227:00 amRNSStudy using Parsortix in head and neck cancer
13th Sep 20227:00 amRNSNew poster presented at ASCP Meeting
12th Sep 20227:30 amRNSNovel assay predicts malignancy in pelvic mass
1st Sep 20227:00 amRNSNotice of Interim Results and Webcast
28th Jul 20227:00 amRNSNovel insight into metastasis in NSCLC patients
20th Jul 20222:33 pmRNSHolding(s) in Company
20th Jul 20227:00 amRNSNEW STUDY OF PARSORTIX SYSTEM IN NSCLC
19th Jul 202210:00 amRNSDirector/PDMR Shareholding
15th Jul 20227:00 amRNSResults of Capital Raise
14th Jul 20225:24 pmRNSRetail Offer via PrimaryBid
14th Jul 20225:23 pmRNSProposed Placing and Retail Offer
8th Jul 20225:30 pmRNSIssue of Equity
29th Jun 20224:35 pmRNSResult of 2022 Annual General Meeting
27th Jun 20227:00 amRNSSpread of breast cancer accelerates during sleep
23rd Jun 20226:24 pmRNSIssue of Equity
22nd Jun 20227:00 amRNSSecured contract from pharma services customer
16th Jun 20227:00 amRNSPredicting immunotherapy response in SCLC
14th Jun 20227:00 amRNSPotential role of invasive cellular protrusions
30th May 20227:00 amRNSPartnership with major United States urology group
27th May 20227:00 amRNSMolecular characterisation of CTCs
25th May 20224:35 pmRNSPrice Monitoring Extension
25th May 202212:30 pmRNSANGLE receives FDA clearance for Parsortix
20th May 20227:00 amRNSProstate Cancer UK funds new study using Parsortix
28th Apr 20227:00 amRNSPreliminary Results
20th Apr 20227:00 amRNSNotice of Preliminary Results and Webcast
14th Apr 20227:00 amRNSPoster on Parsortix system presented at AACR 2022
1st Apr 20227:00 amRNSIdentifying drug targets in cancer metastasis
29th Mar 20227:00 amRNSRapid information on patient response to therapies
25th Mar 20227:00 amRNSIdentifying therapeutic targets in TNBC patients
15th Mar 20227:00 amRNSUpdate on laboratory accreditation
9th Mar 20224:41 pmRNSSecond Price Monitoring Extn
9th Mar 20224:36 pmRNSPrice Monitoring Extension
2nd Mar 20226:29 pmRNSHolding(s) in Company
18th Feb 20225:13 pmRNSIssue of Equity
21st Jan 20227:00 amRNSPotential in immunotherapy treatment selection
17th Jan 20227:00 amRNSConcordance of Parsortix with tissue biopsy
13th Jan 20227:00 amRNSUpdate on lab accreditation and ovarian study
10th Jan 20227:00 amRNSInsight into drug resistance in NSCLC
22nd Dec 20216:29 pmRNSIssue of Equity
1st Dec 20216:11 pmRNSIssue of Equity
1st Dec 20217:00 amRNSParsortix in RNA analysis of CTCs as tool in NSCLC
26th Nov 20215:33 pmRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.